Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines

Journal of Drug Targeting

Volumn 15, Issue 7-8, 2007, Pages 457-464

  Greish, Khaled ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

EPR effect; Macromolecular drugs; Micelles; Nanomedicines; Targeted anticancer therapy

Indexed keywords

3 METHYLGLUCOSE; AMINE OXIDASE (FLAVIN CONTAINING); ANGIOTENSIN II; ANTINEOPLASTIC AGENT; BENZOPORPHYRIN DERIVATIVE; BERAPROST; BRADYKININ; COLLAGENASE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INDOMETACIN; IODINATED POPPYSEED OIL; ISOSORBIDE DINITRATE; LIPOSOME; MACROGOL; MATRIX METALLOPROTEINASE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NANOPARTICLE; NITRIC OXIDE; PEROXYNITRITE; PIRARUBICIN; POLYMER; SALICYLIC ACID; UNINDEXED DRUG; VASCULOTROPIN; VASODILATOR AGENT; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

CANCER MORTALITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EXTRAVASATION; DRUG PENETRATION; DRUG RETENTION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FLUID TRANSPORT; HUMAN; KIDNEY CLEARANCE; LYMPHATIC DRAINAGE; MACROMOLECULE; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MOLECULAR SIZE; NANOMEDICINE; NONHUMAN; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TIGHT JUNCTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MACROMOLECULAR SUBSTANCES; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY;

EID: 34547653668     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701539584     Document Type: Review

References (71)

1. Arun, I., Greish, K., Jun, F., Ryoichi, M. and Maeda, H. (2007) High loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials, 10, pp. 1871-1881.
2. Chen, B., Pogue, BW, Luna, JM, Hardman, RL, Hoopes, PJ and Hasan, T. (2006) Tumor vascular permeabilization by vascular-targeting photosensitization: Effects, mechanism, and therapeutic implications. Clin Cancer Res, 12, pp. 917-923.
3. Courtice, FC (1963) The origin of lipoproteins in lymph. Lymph and lymphatic system, pp. 89-126. C.C. Thomas, Springfield, IL
4. Cseko, C., Bagi, Z. and Koller, A. (2004) Biphasic effect of hydrogen peroxide on skeletal muscle arteriolar tone via activation of endothelial and smooth muscle signaling pathways. J Appl Physiol, 3, pp. 1130-1137.
5. Davies, CL, Berk, DA, Pluen, A. and Jain, RK (2002) Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer, 6, pp. 1639-1644.
6. Dougherty, TJ, Gomer, CJ, Henderson, BW, Jori, G., Kessel, D., Korbelik, M., Moan, J. and Peng, Q. (1998) Photodynamic therapy. J Natl Cancer Inst, 90, pp. 889-905.
7. Duncan, R. (1999) Polymer conjugates for tumor targeting and interacytoplasmic delivery. The EPR effect as a common gateaway?. Pharm Sci Technol Today, 2, pp. 441-449.
8. Fang, J., Sawa, T., Akaike, T. and Maeda, H. (2002) Tumor-targeted delivery of PEG-conjugated-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res, 62, pp. 3138-3143.
9. Fingar, VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg, 14, pp. 323-328.
10. Folkman, J. (1971) Tumor angiogenesis in cancer, Therapeutic implications. N Engl J Med, 285, pp. 1182-1186.
11. Folkman, J. (1995) Angiogenesis in cancer, vasculae, rheumatoid and other disease. Nat Med, 1, pp. 27-31.
12. Gabizon, AA (2001) Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest, 19, pp. 424-436.
13. Gabizon, A. and Martin, F. (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin, Rationale for use in solid tumours. Drugs, 54, pp. 15-21.
14. Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A. and Maeda, H. (2003) Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet, 42, pp. 1089-1105.
15. Greish, K., Sawa, T., Fang, J., Akaike, T. and Maeda, H. (2003) SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release, 97, pp. 219-230.
16. Greish, K., Nagamitsu, A., Fang, J. and Maeda, H. (2005) Copoly (styrene-maleic-acid)-pirarubicin micelles: High tumor targeting efficiency with low toxicity. Bioconjug Chem, 16, pp. 230-236.
17. Guyton, AC and Hall, JE (2000) The body fluids and kidneys. Textbook of medical physiology, pp. 358-382. WB Saunders, Philadelphia
18. Hashizume, H., Baluk, P., Morikawa, S., McLean, JW, Thurston, G., Roberge, S., Jain, RK and McDonald, DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 56, pp. 1363-1380.
19. Hori, K., Suzuki, M., Tanda, S., Saito, S., Shinozaki, M. and Zhang, QH (1991) Fluctuation in tumor blood flow under normotension and the effect of angiotensin-II induced hypertension. Jpn J Cancer Res, 82, pp. 1309-1316.
20. Hori, K., Saito, S., Nihei, Y., Suzuki, M. and Sato, Y. (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res, 90, pp. 1026-1038.
21. Hori, K., Saito, S., Takahashi, H., Sato, H., Maeda, H. and Sato, Y. (2000) Tumorselective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res, 91, pp. 261-269.
22. Jain, R. (1988) Determinants of tumor blood flow: A review. Cancer Res, 10, pp. 2641-2658.
23. Jain, R. (1994) Barriers to drug delivery in solid tumors. Sci Am, 271, pp. 58-65.
24. Kobayashi, M., Oda, T. and Maeda, H. (1988) Protein binding of macromolecular anticancer agent SMANCS: Characterization of poly (styrene-co-maleic acid) derivatives as an albumin binding ligand. J Bioact Compat Polym, 3, pp. 319-333.
25. Konno, T. (1992) Targeting chemotherapy for hepatoma: Arterial administration of anticancer drugs dissolved in lipiodol. Eur J Cancer, 28, pp. 403-409.
26. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M. and Miyauchi, Y. (1984) Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer, 54, pp. 2367-2374.
27. Kopecek, J., Kopeckova, P., Minko, T., Lu, ZR and Peterson, CM (2001) Water-soluble polymers in tumor targeted delivery. J Control Release, 74, pp. 147-158.
28. Kuruppu, D., Christophi, C., Maeda, H. and O'Brien, PE (2002) Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol. J Surg Res, 103, pp. 47-54.
29. Leaf, C. (2004) Why we're losing the war on cancer (and how to win it). Fortune, 149:76, pp. 84-86.
30. Leu, A., Berk, D., Lymboussaki, A., Alitalo, K. and Jain, R. (2000) Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res, 60, pp. 4324-4327.
31. Miyamoto, Y., Kojima, Y. and Maeda, H. (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer, 67, pp. 975-980.
32. Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev, 6, pp. 181-202.
33. Maeda, H. (2001) Enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41, pp. 189-207.
34. Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst, 6, pp. 193-210.
35. Maeda, H., Takeshita, J. and Kanamaru, R. (1979) A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res, 2, pp. 81-87.
36. Maeda, H., Konno, T., Iwai, K., Maki, S. and Tashiro, S. (1984) Tumor selective drug delivery with lipid contrast medium (smancs/lipiodol): Sustained antitumor effect, enhanced diagnostic value and quantification of dosage regimen. Gan To Kagaku Ryoho, 4, pp. 814-826.
37. Maeda, H., Matsumura, Y. and Oda, T. (1986) Cancer selective macromolecular therapeutics: Tailoring of an antitumor protein drug. Protein tailoring for food and medical uses, pp. 353-382. Dekker Inc., New York
38. Maeda, H., Takeshita, J. and Kimura, M. (1988) Improvement of pharmacological properties of protein drugs by tailoring with synthetic polymers. J Bioact Compat Polym, 3, pp. 27-43.
39. Maeda, H., Matsumura, Y. and Kato, H. (1988) Purification and identification of [hydroxyprolyl3] bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem, 31, pp. 16051-16054.
40. Maeda, H., Noguchi, Y., Sato, K. and Akaike, T. (1994) Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res, 85, pp. 331-334.
41. Maeda, H., Akaike, T., Noguchi, Y. and Sakata, Y. (1996) Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology, 33, pp. 222-230.
42. Maeda, H., Okamoto, T., Maruo, K. and Akaike, T. (1999) Kallikrein-kinin in infection and cancer. Immunopharmacology, 43, pp. 115-128.
43. Maeda, H., Sawa, T. and Konno, T. (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release, 74, pp. 47-61.
44. Maeda, H., Fang, J., Inuzuka, T. and Kitamoto, Y. (2003) Vascular permeability enhancement in solid tumors: Various factors, mechanisms involved and its implications. Int Immunopharmacol, 3, pp. 319-328.
45. Markwalder, J. and Starling, EH (1914) On the constancy of the systolic output under varying conditions. J Physiol, 48, pp. 348-356.
46. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS. Cancer Res, 46, pp. 6387-6392.
47. Matsumura, Y., Kimura, M., Yamamoto, T. and Maeda, H. (1988) Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn J Cancer Res, 79, pp. 1327-1334.
48. Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T. and Maeda, H. (1991) Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res, 6, pp. 732-741.
49. Minko, T., Kopeckova, P., Pozharov, V., Jensen, KD and Kopecek, J. (2000) The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm Res, 5, pp. 505-514.
50. Nagamitsu, A., Inuzuka, T., Kawasuji, M. and Maeda, H. (2003) Recent advances in SMANCS/lipiodol therapy enhanced targeting and delivery efficacy using vascular modulators. Drug Deliv Syst, 18, pp. 438-447.
51. Natarajan, V., Scribner, WN, Al-Hassani, M. and Vepa, S. (1998) Reactive oxygen species signaling through regulation of protein tyrosine phosphorylation in endothelial cells. Environ Health Perspect, 106, pp. 1205-1212.
52. Noguchi, Y., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T. and Maeda, H. (1998) Early phase of tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res, 89, pp. 307-314.
53. Noguchi, R., Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Yanase, K., Namisaki, T., Kitade, M., Yamazaki, M., Mitoro, A., Tsujinoue, H., Imazu, H., Masaki, T. and Fukui, H. (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res, 9, pp. 6038-6045.
54. Oda, T. and Maeda, H. (1987) Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its action by conjugation with lipophylic styrene-maleic acid copolymer. Cancer Res, 47, pp. 3206-3211.
55. Okamoto, T., Akaike, T., Sawa, T., Miyamoto, Y., van der Vliet, A. and Maeda, H. (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem, 276, pp. 29596-29602.
56. 2 in vascular smooth muscle cells. Biochim Biophys Acta, 1265, pp. 67-72.
57. Rihova, B., Bilej, M., Vetvicka, V., Ulbrich, K., Strohalm, J., Kopecek, J. and Duncan, R. (1989) Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials, 5, pp. 335-342.
58. Senger, DR, Galli, SJ, Dvorak, A., Perruzzi, C., Harvey, V. and Dvorak, F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, pp. 983-985.
59. Skinner, S., Tutton, P. and O'Brien, PE (1990) Microvascular architecture of experimental colon tumors in the rat. Cancer Res, 50, pp. 2411-2417.
60. Stroh, M., Zimmer, JP, Duda, DG, Levchenko, TS, Cohen, KS, Brown, EB, Scadden, DT, Torchilin, VP, Bawendi, MG, Fukumura, D. and Jain, RK (2005) Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med, 6, pp. 678-682.
61. Suzuki, M., Hori, K., Abe, Z., Saito, S. and Sato, H. (1981) A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst, 67, pp. 663-669.
62. Suzuki, M., Takahashi, T. and Sato, T. (1987) Medial regression and its functional significance in tumor-supplying host arteries. Cancer, 59, pp. 444-450.
63. Tanaka, S., Akaike, T., Fang, J., Sawa, T., Ogawa, M., Beppu, T. and Maeda, H. (2003) Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin I2 analogue beraprost sodium. J Drug Target, 11, pp. 45-52.
64. Uemura, H., Nakaigawa, N., Ishiguro, H. and Kubota, Y. (2005) Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets, 5, pp. 307-323.
65. Weir, EK and Archer, SL (1995) The mechanism of acute hypoxic pulmonary vasoconstriction: The tale of two channels. FASEB J, 9, pp. 183-189.
66. Akaike, T. and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res, 58, pp. 159-165.
67. Akaike, T., Hyashida, K., Okamoto, T., Okuyama, A. and Maeda, H. (2001) Enhanced vascular permeability in solid tumor involving peroxynitite and matrix metalloproteinases. Jpn J Cancer Res, 92, pp. 439-451.
68. 2+ and other cellular metabolites. Gen Pharmacol, 33, pp. 325-336.
69. Yazawa, K., Fujimori, M., Amano, J., Kano, Y. and Taniguchi, S. (2000) Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther, 2, pp. 269-274.
70. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, DA, Torchilin, VP and Jain, RK (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res, 55, pp. 3752-3756.
71. Zeidman, I., Copeland, BE and Warren, S. (1955) Experimental studies on the spread of cancer in the lymphatic system. II. Absence of a lymphatic supply in carcinoma. Cancer (Philadelphia), 8, pp. 123-127.